Insmed Inc (INSM)

NASDAQ
Currency in USD
98.18
+1.52(+1.57%)
Closed·
After Hours
98.50+0.32(+0.33%)
·
INSM Scorecard
Full Analysis
Analysts do not anticipate the company will be profitable this year
INSM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
95.9699.39
52 wk Range
60.40106.83
Key Statistics
Edit
Prev. Close
96.66
Open
96.41
Day's Range
95.96-99.39
52 wk Range
60.4-106.83
Volume
3.25M
Average Vol. (3m)
3.71M
1-Year Change
27.99%
Book Value / Share
0.55
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
INSM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
113.22
Upside
+15.31%
Members' Sentiments
Bearish
Bullish
ProTips
Liquid assets exceed short term obligations

Insmed Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Insmed Inc Company Profile

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Insmed Inc SWOT Analysis


Market Opportunities
Delve into Insmed's strategy in targeting underserved patient populations, potentially driving significant revenue growth and market leadership in rare diseases
Financial Outlook
Analysts project EPS of -5.57 and -4.93 for the next two fiscal years, with price targets ranging from $80 to $109, reflecting strong growth potential
Pipeline Potential
Explore Insmed's promising pipeline, including brensocatib for bronchiectasis, with projected U.S. sales of up to $3.8 billion by 2034
Rare Disease Pionee
Insmed's focus on serious and rare diseases positions it as a significant player in niche markets with high unmet medical needs and potential for premium pricing
Read full SWOT analysis

Insmed Inc Earnings Call Summary for Q1/2025

  • Q1 2025 revenue beat expectations at $92.82M, but EPS missed at -$1.42 vs -$1.35 forecast
  • Strong international growth, with Japan and Europe sales up ~50%; U.S. ARIKAYCE sales increased 14%
  • Stock fell 0.82% to $67.72 pre-market despite revenue beat, reflecting EPS miss and spending concerns
  • Company maintains $1.2B cash balance, prepares for brensocatib launch with FDA decision expected by August 12
  • Insmed forecasts 29% revenue growth for FY2025, continuing 22% CAGR over past five years
Last Updated: 05/08/2025, 09:48 AM
Read Full Transcript

Compare INSM to Peers and Sector

Metrics to compare
INSM
Peers
Sector
Relationship
P/E Ratio
−18.4x−3.5x−0.5x
PEG Ratio
1.42−0.110.00
Price / Book
188.1x3.0x2.6x
Price / LTM Sales
48.9x27.8x3.2x
Upside (Analyst Target)
13.0%145.7%45.4%
Fair Value Upside
Unlock11.5%6.9%Unlock

Analyst Ratings

19 Buy
0 Hold
0 Sell
Ratings:
19 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 113.22
(+15.31% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-1.42 / -1.35
Revenue / Forecast
92.82M / 90.78M
EPS Revisions
Last 90 days

INSM Income Statement

People Also Watch

125.84
CRWV
-9.00%
539.16
GEV
-0.04%
187.33
CRCL
-7.67%
37.480
SMR
+4.05%
56.08
OKLO
+1.14%

FAQ

What Is the Insmed (INSM) Stock Price Today?

The Insmed stock price today is 98.18

What Stock Exchange Does Insmed Trade On?

Insmed is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Insmed?

The stock symbol for Insmed is "INSM."

What Is the Insmed Market Cap?

As of today, Insmed market cap is 18.65B.

What Is Insmed's Earnings Per Share (TTM)?

The Insmed EPS (TTM) is -5.89.

When Is the Next Insmed Earnings Date?

Insmed will release its next earnings report on Jul 31, 2025.

From a Technical Analysis Perspective, Is INSM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Insmed Stock Split?

Insmed has split 2 times.

How Many Employees Does Insmed Have?

Insmed has 1271 employees.

What is the current trading status of Insmed (INSM)?

As of Jul 13, 2025, Insmed (INSM) is trading at a price of 98.18, with a previous close of 96.66. The stock has fluctuated within a day range of 95.96 to 99.39, while its 52-week range spans from 60.40 to 106.83.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.